innoscripta SE (XTER:1INN) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:1INN innoscripta SE XTER:1INN
29 GF Score
Price €87.30
! 2 Warning Signs
View Full Analysis

What is innoscripta SE Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of innoscripta SE is: No Data: Cannot be evaluated.

innoscripta SE  (XTER:1INN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

innoscripta SE Risk Assessment Related Terms

XTER:1INN vs CRM, SHOP, UBER: Risk Assessment Comparison

For the Software - Application subindustry, innoscripta SE's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

innoscripta SE Risk Assessment vs Software Industry

For the Software industry and Technology sector, innoscripta SE's Risk Assessment distribution charts can be found below:

* The bar in red indicates where innoscripta SE's Risk Assessment falls into.


XTER:1INN
29GF Score
innoscripta SE XTER:1INN
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

innoscripta SE Business Description

Address Bahnhofstr. 17, Tutzing, BY, DEU, 82327
innoscripta SE is a German software company that develops cloud-based compliance software for research and development activities. Its platform helps companies document, manage, and report R&D projects in line with national and international funding and tax incentive requirements, particularly in Germany and other European markets. The company serves businesses of various sizes, from mid-sized enterprises to large corporations, that seek to claim research and development tax credits or grants. Its revenue model combines subscription fees for its software-as-a-service platform with consulting and advisory services related to R&D tax incentives and funding programs. By integrating documentation workflows with regulatory requirements, innoscripta aims to reduce the administrative burden and compliance risk associated with claiming R&D incentives. The company is headquartered in Germany and focuses primarily on the European market.
29GF Score

Get the complete analysis for XTER:1INN

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.30
Price